Half-year sales up 19% at Oxford Instruments:
This article was originally published in Clinica
UK-based advanced instrumentation group Oxford Instruments has seen turnover rise 19% in the first half to £65.5 million. International sales accounted for 85% of turnover. After-tax profit increased to £5.9 million compared with £5.1 million in the comparable period of the previous year. CEO Peter Williams noted a small drop in profits in the MRI joint venture with Siemens and said that pricing pressures are increasingly felt in nearly all Oxford Instruments' markets.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.